KR970032890A - Peptide with human immunomodulatory function against Hantan virus - Google Patents

Peptide with human immunomodulatory function against Hantan virus Download PDF

Info

Publication number
KR970032890A
KR970032890A KR1019950065413A KR19950065413A KR970032890A KR 970032890 A KR970032890 A KR 970032890A KR 1019950065413 A KR1019950065413 A KR 1019950065413A KR 19950065413 A KR19950065413 A KR 19950065413A KR 970032890 A KR970032890 A KR 970032890A
Authority
KR
South Korea
Prior art keywords
peptides
virus
lymphocytes
hantan virus
cytotoxic
Prior art date
Application number
KR1019950065413A
Other languages
Korean (ko)
Other versions
KR0166425B1 (en
Inventor
김태연
황유경
조성유
박증석
최윤
이기영
정홍석
문홍모
Original Assignee
허영섭
재단법인 목암생명공학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허영섭, 재단법인 목암생명공학연구소 filed Critical 허영섭
Priority to KR1019950065413A priority Critical patent/KR0166425B1/en
Publication of KR970032890A publication Critical patent/KR970032890A/en
Application granted granted Critical
Publication of KR0166425B1 publication Critical patent/KR0166425B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 한탄 바이러스에 대한 인체의 면역성 조절기능을 가지는 신규한 일련의 펩타이드군에 관한 것이다. 좀더 구체적으로, 본 발명은 한탄 바이러스의 N 단백질과 G1, G2 단백질 항원중 한탄 바이러스에 대한 세포독성 T-임파구(cytotoxic T lymphocytes, CTL)를 유도하거나, 그 바이러스에 대해 면역관용(immunological tolerance)을 유도하는 항원의 특정부위(epitope)에 해당하는 펩타이드의 아미노산 서열에 관한 것이다. 본 발명의 H1, H2, H3, H4, H7, H8, H11, H33, H37 등 9종의 신규한 펩타이드는 인체내에 존재하는 한탄 바이러스 항원을 인지하는 CTL을 활성화시키며, 그 CTL에 의해 다시 인지될 수 있는 펩타이드로서, 한탄 바이러스 관련 질환의 예방과 치료에 사용될 수 있을 것이다.The present invention relates to a novel series of peptides having an immunomodulatory function of the human body against hantan virus. More specifically, the present invention induces cytotoxic T-lymphocytes (CTLs) against the Hantan virus of N protein and G1 and G2 protein antigens of the Hantan virus, or provides immunological tolerance against the virus. It relates to the amino acid sequence of the peptide corresponding to the epitope of the antigen to be induced. Nine novel peptides, including H1, H2, H3, H4, H7, H8, H11, H33, H37, of the present invention activate CTLs that recognize the Hantan virus antigens present in the human body, and can be recognized by the CTLs again. As a peptide which can be used for the prevention and treatment of a disease of the hantan virus.

Description

한탄 바이러스에 대한 인체 면역조절기능을 가진 펩타이드Peptide with human immunomodulatory function against Hantan virus

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

하기와 같은 한탄 바이러스 펩타이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: SMLSYGGNVL(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides comprising the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTL) and exhibit apoptosis by the virus: SMLSYGGNVL (wherein the amino acid sequence is described according to the nomenclature of IUPAC) .) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: YLTSFVVPI(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTL) and exhibit cytotoxicity by the virus: YLTSFVVPI (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: ILLKALYML(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTL) and exhibit cytotoxicity by the virus: ILLKALYML (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: GLYPAQIKA(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTL) and exhibit cytotoxicity by the virus: GLYPAQIKA (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: KLLPDTAAV(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTL) and exhibit cytotoxicity by the virus: KLLPDTAAV (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: TLAQSLIDV(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides comprising the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTLs) and exhibit cytotoxicity by the virus: TLAQSLIDV (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: VMASLVWPV(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTLs) and exhibit cytotoxicity by viruses: VMASLVWPV (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: GIFSGNWIV(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTLs) and exhibit cytotoxicity by viruses: GIFSGNWIV (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 하기와 같은 한탄 바이러스 펩바이드 및 그의 기능적 등가물을 포함하며, 세포 독성 T 임파구(CTL)에 의해 인지되어 바이러스에 의해 세포살해능을 나타내는 펩타이드: VLLSILCPVYL(상기에서, 아미노산 서열은 IUPAC의 명명법에 따라 기재 하였다.)Peptides including the following Hantan virus peptides and functional equivalents thereof, which are recognized by cytotoxic T lymphocytes (CTLs) and exhibit cytotoxicity by viruses: VLLSILCPVYL (wherein the amino acid sequence is described according to the nomenclature of IUPAC) ) 제 1항 내지 제 9항의 펩타이드를 1종 이상 사용하여 한탄 바이러스에 대한 특이성을 가진 세포독성 T 임파구(CTL)를 유도하는 방법.A method of inducing cytotoxic T lymphocytes (CTLs) having specificity for a hantan virus using at least one peptide of claim 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950065413A 1995-12-29 1995-12-29 Hantan virus-derived peptide having immuno-modulation function in human KR0166425B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950065413A KR0166425B1 (en) 1995-12-29 1995-12-29 Hantan virus-derived peptide having immuno-modulation function in human

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950065413A KR0166425B1 (en) 1995-12-29 1995-12-29 Hantan virus-derived peptide having immuno-modulation function in human

Publications (2)

Publication Number Publication Date
KR970032890A true KR970032890A (en) 1997-07-22
KR0166425B1 KR0166425B1 (en) 1999-01-15

Family

ID=19447031

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950065413A KR0166425B1 (en) 1995-12-29 1995-12-29 Hantan virus-derived peptide having immuno-modulation function in human

Country Status (1)

Country Link
KR (1) KR0166425B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100383554B1 (en) * 2000-04-06 2003-05-12 성백린 peptides inducing human immune response to Hantaan & Sin Nombre virus

Also Published As

Publication number Publication date
KR0166425B1 (en) 1999-01-15

Similar Documents

Publication Publication Date Title
ATE188612T1 (en) CONJUGATES OF WEAKLY IMMUNOGENIC ANTIGENS AND SYNTHETIC PEPTIDE CARRIERS AND VACCINES CONTAINING SAME
KR960704923A (en) Peptides Capable of Inducing Immune Response to HIV and Anti-AIDS Agent for Preventing and Curing AIDS
ES2138784T3 (en) SYNTHETIC ANTIGENS FOR THE DETECTION OF ANTIBODIES AGAINST THE HEPATITIS C VIRUS.
WO1992017493A3 (en) Peptides and mixtures thereof for detecting antibodies to hepatitis c virus (hcv)
ES2307496T4 (en) HIV vaccine, antigen and peptide compositions
CA2391843A1 (en) Hcv vaccine compositions
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
KR910019641A (en) Serum Reactive Epitopes on Proteins of Human Papilloma Virus (HPV) 18
EP0491628A3 (en) Lipopeptide inducing t-cytotoxic lymphocytes and their use as vaccines
ATE382696T1 (en) IMMUNOREACTIVE ANTIGENS OF THE HEPATITIS E VIRUSE
KR970032890A (en) Peptide with human immunomodulatory function against Hantan virus
WO2004005316A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
ATE435034T1 (en) EXPRESSION AND CHARACTERIZATION OF AN HIV-1 ENVELOPE PROTEIN ASSOCIATED WITH A BROADLY REACTIVE NEUTRALIZING ANTIBODY RESPONSE.
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
EP0955366A4 (en) Antigenic protein originating in malassezia
NO983054L (en) Viral recombinant pseudoparticles and use as vaccines and as anti-tumor agents
KR970032887A (en) Peptides with Human Immune Regulation Against Hepatitis C Virus
KR950028783A (en) Peptides with Human Immune Regulation Against Hepatitis C Virus
DE69333111D1 (en) NATURAL HUMAN IGM ANTIBODIES
KR890009972A (en) Peptides, methods of preparation thereof, their use to obtain antibodies, and the use of antibodies to inhibit PAI 1 activity in human blood
WO2002051865A3 (en) Proteinic antigens inducing antibodies neutralising hiv virus
FR2737209B1 (en) PEPTIDE CAPABLE OF BEING RECOGNIZED BY ANTIBODIES RECOGNIZING THE C33 ANTIGEN OF HEPATITIS C VIRUS
EP1310512A3 (en) Hcv core protein sequences
IT1270941B (en) HCV PEPTIDES AND THEIR USES.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040921

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee